The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Time-dependent prognostic value of MRD assessments after ide-cel in patients with myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into a recent publication exploring the value of measurable residual disease (MRD) assessments in patients with multiple myeloma treated with idecabtagene vicleucel (ide-cel) in the Phase II KarMMa trial (NCT03361748). Dr Paiva explains that the prognostic value of MRD status and immunofixation status is time-dependent, and further highlights other novel biomarkers that have been identified in this setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
